KEY TAKEAWAYS
- The study aimed to investigate the antitumor and protumor immune activities and their ratios as significant prognostic biomarkers in mTNBC pts.
- Researchers noticed that high levels of CD4/FOXP3 and CD8/CD163 significantly improved 1-year overall survival in de novo mTNBC pts.
Triple-negative breast cancer (TNBC) stands out as the most aggressive subtype among breast cancers. Jeffry Beta Tenggara and his team aimed to analyze antitumor and protumor immune activities, focusing on their ratios as significant prognostic biomarkers in the context of metastatic TNBC (mTNBC).
Researchers performed an inclusive analysis through a multicenter cohort study involving 103 de novo mTNBC patients (pts). The expression levels of CD8 and CD163 were evaluated using immunohistochemistry staining, while CD4 and FOXP3 were assessed through double-staining immunohistochemistry. Additionally, PD-L1 was examined using both immunohistochemistry and RT-PCR methods.
About 103 de novo mTNBC pts were subjected to multivariate analysis, revealing that high CD4/FOXP3 (HR 1.857; 95% CI 1.049-3.288; p = 0.034) and the CD8/CD163 ratio (HR 2.089; 95% CI 1.174-3.717; p = 0.012) significantly improved 1-year overall survival (OS).
Kaplan-Meier analysis demonstrated a substantial association between high levels of CD4 (p = 0.023), CD8 (p = 0.043), CD4/FOXP3 (p = 0.016), CD8/FOXP3 (p = 0.005), CD8/CD163 (p = 0.005) ratios and a higher rate of 1-year OS.
Additionally, 1-year OS exhibited a direct correlation with antitumor CD4 (R = 0.233; p = 0.018) and CD8 (R = 0.219; p = 0.026), and an indirect correlation with protumor CD163 and FOXP3 through CD4/FOXP3 (R = 0.282; p = 0.006), CD4/CD163 (R = 0.239; p = 0.015), CD8/FOXP3 (R = 0.260; p = 0.008), and CD8/CD163 (R = 0.258; p = 0.009).
The study concluded that elevated levels of CD4/FOXP3 and CD8/CD163 significantly enhance 1-year overall survival in de novo mTNBC pts. Consequently, applying these markers is recommended for prognosis determination and guiding individualized treatment decisions.
Source: https://pubmed.ncbi.nlm.nih.gov/38308298/
Tenggara JB, Rachman A, Prihartono J, et al. (2024). The relationship between high ratios of CD4/FOXP3 and CD8/CD163 and the improved survivability of metastatic triple-negative breast cancer patients: a multicenter cohort study. BMC Res Notes. 2024 Feb 2;17(1):44. doi: 10.1186/s13104-024-06704-z. PMID: 38308298; PMCID: PMC10835864.
